Sulkowski Jason P, Raval Mehul V, Browne Marybeth
Division of Pediatric Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA.
Pediatr Surg Int. 2013 Aug;29(8):771-6. doi: 10.1007/s00383-013-3318-4. Epub 2013 Jun 14.
The rarity of infantile fibrosarcoma (IF) has precluded comprehensive treatment evaluation. The purpose of this study was to better define the extent of surgical resection required and the role of chemotherapy.
Patients (0-2 years) with IF were evaluated from the National Cancer Data Base (1985-2007). Survival was estimated using the Kaplan-Meier method stratifying patients by margin status and treatment with or without chemotherapy.
Of the 224 patients, 171 (76.3 %) were <1 year of age. Of the 64 (28.6 %) with positive margins, 36 (56.3 %) had microscopic disease, 12 (18.8 %) had macroscopic disease, and 16 (25 %) had unknown margin status; none were found to have metastases. Most were managed with surgical resection (171, 76.4 %). The proportion treated with both surgery and chemotherapy increased over time (18-40 %, p = 0.025). Disease-free survival was 90.6 %. No significant survival difference was noted in this retrospective, non-randomized cohort based on margin status, nodal involvement, tumor size, or treatment modality.
The use of multimodal therapy has increased over time. There was a small increase in survival associated with negative margins and the use of multimodal therapy, however, neither result reached significance. Future studies investigating tumor biology and chemosensitivity will likely determine the optimal management of IF.
婴儿纤维肉瘤(IF)较为罕见,因此难以进行全面的治疗评估。本研究的目的是更明确所需手术切除的范围以及化疗的作用。
从国家癌症数据库(1985 - 2007年)中评估患有IF的患者(0 - 2岁)。采用Kaplan-Meier方法估计生存率,根据切缘状态以及是否接受化疗对患者进行分层。
224例患者中,171例(76.3%)年龄小于1岁。64例(28.6%)切缘阳性的患者中,36例(56.3%)有微小病灶,12例(18.8%)有肉眼可见病灶,16例(25%)切缘状态不明;未发现有转移的患者。大多数患者接受了手术切除(171例,76.4%)。接受手术和化疗的比例随时间增加(18% - 40%,p = 0.025)。无病生存率为90.6%。在这个回顾性、非随机队列中,基于切缘状态、淋巴结受累情况、肿瘤大小或治疗方式,未观察到显著的生存差异。
随着时间推移,多模式治疗的应用有所增加。切缘阴性和使用多模式治疗与生存率有小幅提高,但均未达到显著水平。未来关于肿瘤生物学和化疗敏感性的研究可能会确定IF的最佳治疗方案。